London-based fertility tech startup, Béa Fertility, announced that it has raised £2.5M to introduce its ‘groundbreaking’ fertility treatment to early adopters in the UK market.
The round was led by Octopus Ventures and joined by JamJar and Forward Partners, with additional participation from existing investors Calm/Storm and Q Ventures. This raise brings Béa Fertility’s total funding to date to $4.2M.
In a world where access to fertility care is often limited and costly, Béa Fertility, founded by Tess Cosad and George Thomas, is on a mission to redefine the landscape. With their at-home fertility treatment, Béa Fertility is making clinical-grade care accessible to everyone.
This new fund will enable the company to make the first Béa Treatment Kits available to the public.
The first Béa treatment is available to purchase online via Béa’s website now, says the company.
The first users to purchase a kit will pay just £350 for three ICI treatment cycles, with one Treatment Kit delivered at the beginning of each menstrual cycle throughout the three-month treatment program.
The Béa Treatment eliminates the need for invasive hormone injections and clinical procedures, providing a more accessible and affordable option.
Read more on Tech Gist Africa: